Related Experiment Video
Updated: Jan 18, 2026

05:49
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
Published on: May 5, 2021
5.5K
Hyperlactataemia in phenformin-treated diabetics
British Medical Journal
|January 22, 1972
Summary
Phenformin medication in diabetic patients increases blood lactate levels and the lactate/pyruvate ratio, especially after glucose intake. Discontinuing phenformin normalizes these levels, indicating the drug
Area of Science:
- Biochemistry
- Endocrinology
- Pharmacology
Background:
- Diabetic patients often exhibit altered metabolic profiles.
- Phenformin is a medication used in diabetes management.
- Lactate metabolism is crucial in overall metabolic health.
Purpose of the Study:
- To investigate the effect of phenformin on blood lactate levels in diabetic patients.
- To examine the impact of phenformin on the lactate/pyruvate ratio.
- To assess the reversibility of phenformin-induced metabolic changes.
Main Methods:
- Observational study of diabetic patients on phenformin.
- Measurement of fasting blood lactate levels.
- Intravenous glucose loading test with lactate and pyruvate ratio analysis.
- Monitoring of metabolic parameters after drug withdrawal.
Main Results:
- Elevated fasting blood lactate levels were observed in patients taking therapeutic doses of phenformin.
- An intravenous glucose load exacerbated hyperlactatemia and increased the lactate/pyruvate ratio.
- Discontinuation of phenformin resulted in normalization of blood lactate and a decrease in the lactate/pyruvate ratio.
Conclusions:
- Phenformin therapy in diabetic patients is associated with elevated blood lactate levels.
- The drug interferes with lactate metabolism, particularly under glucose challenge.
- Phenformin-induced hyperlactatemia is reversible upon drug withdrawal.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Inborn Errors of Metabolism
697
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
697
Hypoglycemia and Glucagon
838
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
838
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Pathophysiology of Diabetes
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.2K
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K

